Robert M. Knabb

5.6k total citations · 1 hit paper
98 papers, 4.3k citations indexed

About

Robert M. Knabb is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Robert M. Knabb has authored 98 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 46 papers in Cardiology and Cardiovascular Medicine and 20 papers in Genetics. Recurrent topics in Robert M. Knabb's work include Blood Coagulation and Thrombosis Mechanisms (65 papers), Atrial Fibrillation Management and Outcomes (31 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (20 papers). Robert M. Knabb is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (65 papers), Atrial Fibrillation Management and Outcomes (31 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (20 papers). Robert M. Knabb collaborates with scholars based in United States, Germany and Sweden. Robert M. Knabb's co-authors include Ruth R. Wexler, Pancras C. Wong, Donald Pinto, Joseph M. Luettgen, Patrick Y. S. Lam, Charles A. Kettner, Richard Alexander, Lawrence J. Mersinger, Mimi L. Quan and Kan He and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Robert M. Knabb

98 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

2011 401 citations Samuel Z. Goldhaber, Alain Leizorovicz et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Robert M. Knabb

Since Specialization

Citations

This map shows the geographic impact of Robert M. Knabb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Knabb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Knabb more than expected).

Fields of papers citing papers by Robert M. Knabb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Knabb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Knabb. The network helps show where Robert M. Knabb may publish in the future.

Co-authorship network of co-authors of Robert M. Knabb

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Knabb. A scholar is included among the top collaborators of Robert M. Knabb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Knabb. Robert M. Knabb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties 2014 ·Bioorganic & Medicinal Chemistry Letters ·Michael J. Orwat, Jennifer X. Qiao, Kan He, Alan R. Rendina, Joseph M. Luettgen, Karen A. Rossi, Baomin Xin, Robert M. Knabb, Ruth R. Wexler, Patrick Y. S. Lam, Donald Pinto	7
2	Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor 2013 ·Bioorganic & Medicinal Chemistry Letters ·E. Scott Priestley, (unknown), Jinglan Zhou, Jiacheng Zhou, Eddine Saiah, Robert V. Stanton, Leslie A. Robinson, Joseph M. Luettgen, Anzhi Wei, (unknown), Robert M. Knabb, Pancras C. Wong, Ruth R. Wexler	23
3	Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Xiaojun Zhang, Peter W. Glunz, Wen Jiang, (unknown), (unknown), Frank Barbera, (unknown), Alan R. Rendina, Anzhi Wei, (unknown), Karen A. Rossi, Joseph M. Luettgen, Pancras C. Wong, Robert M. Knabb, Ruth R. Wexler, E. Scott Priestley	7
4	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients breakdown → 2011 ·New England Journal of Medicine ·Samuel Z. Goldhaber, Alain Leizorovicz, Ajay K. Kakkar, Sylvia Haas, Geno J. Merli, Robert M. Knabb, Jeffrey I. Weitz	401
5	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor 2011 ·European Journal of Drug Metabolism and Pharmacokinetics ·Kan He, Joseph M. Luettgen, Donglu Zhang, Bing He, James E. Grace, Baomin Xin, Donald Pinto, Pancras C. Wong, Robert M. Knabb, Patrick Y. S. Lam, Ruth R. Wexler, Scott Grossman	71
6	Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans 2009 ·Drug Metabolism and Disposition ·Donglu Zhang, Kan He, Nirmala Raghavan, Lifei Wang, James Mitroka, Brad D. Maxwell, Robert M. Knabb, Charles Frost, Alan Schuster, Hao Feng, Zhe-ming Gu, W. Griffith Humphreys, Scott Grossman	89
7	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jennifer X. Qiao, Chong‐Hwan Chang, Daniel L. Cheney, Paul E. Morin, (unknown), (unknown), Tammy C. Wang, Alan R. Rendina, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler, Patrick Y. S. Lam	29
8	Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs 2007 ·Drug Metabolism and Disposition ·Donglu Zhang, Nirmala Raghavan, Shiang-Yuan Chen, Haiying Zhang, Mimi L. Quan, (unknown), (unknown), Patrick Y. S. Lam, Samuel J. Bonacorsi, Robert M. Knabb, Gary L. Skiles, Kan He	46
9	Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits 2007 ·Journal of Thrombosis and Thrombolysis ·Pancras C. Wong, Earl J. Crain, Carol A. Watson, Ruth R. Wexler, Patrick Y. S. Lam, Mimi L. Quan, Robert M. Knabb	28
10	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jennifer X. Qiao, Tammy C. Wang, (unknown), Daniel L. Cheney, Kan He, Alan R. Rendina, Baomin Xin, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler, Patrick Y. S. Lam	17
11	Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues 2006 ·Bioorganic & Medicinal Chemistry Letters ·Jennifer X. Qiao, Xuhong Cheng, Joanne M. Smallheer, Robert A. Galemmo, (unknown), Donald Pinto, Daniel L. Cheney, Kan He, Pancras C. Wong, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler, Patrick Y. S. Lam	18
12	SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa 2004 ·Bioorganic & Medicinal Chemistry Letters ·Joanne M. Smallheer, Richard Alexander, Jianmin Wang, Shuaige Wang, (unknown), Karen A. Rossi, Angela Smallwood, Frank Barbera, Debra Burdick, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler, Prabhakar K. Jadhav	30
13	Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Mimi L. Quan, Christopher D. Ellis, (unknown), Ann Y. Liauw, Patrick Y. S. Lam, Karen A. Rossi, Robert M. Knabb, Joseph M. Luettgen, Matthew Wright, Pancras C. Wong, Ruth R. Wexler	17
14	Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic Agent 2002 ·Cardiovascular Drug Reviews ·Pancras C. Wong, Donald Pinto, Robert M. Knabb	37
15	Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core 2001 ·Bioorganic & Medicinal Chemistry Letters ·John M. Fevig, Donald Pinto, Qi Han, Mimi L. Quan, James R. Pruitt, (unknown), Robert A. Galemmo, Shuaige Wang, Michael J. Orwat, Lori L. Bostrom, Robert M. Knabb, Pancras C. Wong, Patrick Y. S. Lam, Ruth R. Wexler	31
16	Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa 1999 ·Bioorganic & Medicinal Chemistry Letters ·John M. Fevig, (unknown), Pieter F. W. Stouten, Robert M. Knabb, Gilbert N. Lam, Pancras C. Wong, Ruth R. Wexler	11
17	Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa 1998 ·Bioorganic & Medicinal Chemistry Letters ·John M. Fevig, Joseph Cacciola, Richard Alexander, Robert M. Knabb, Gilbert N. Lam, Pancras C. Wong, Ruth R. Wexler	5
18	The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial sar studies 1998 ·Bioorganic & Medicinal Chemistry Letters ·Robert A. Galemmo, Thomas Maduskuie, Celia Dominguez, Karen A. Rossi, Robert M. Knabb, Ruth R. Wexler, Pieter F. W. Stouten	15
19	The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission tomography after coronary thrombolysis. 1987 ·PubMed ·Robert M. Knabb, Steven R. Bergmann, Keith A.A. Fox, Burton E. Sobel	34
20	Enhancement of salvage of reperfused ischemic myocardium by diltiazem 1986 ·Journal of the American College of Cardiology ·Robert M. Knabb, Thomas Rosamond, Keith A.A. Fox, Burton E. Sobel, Steven R. Bergmann	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact